Long-Term Treatment of Ovariectomized Mice with Estradiol or Phytoestrogens as a New Model to Study the Role of Estrogenic Substances in the Heart

Abstract

Epidemiological data reveal that the overall risk for heart disease is lower for premenopausal women compared to age-matched men. However, the beneficial effect for the female sex is lost upon menopause. Thus, it has been suggested that estrogens convey the protective effect for the female sex against heart disease. Numerous natural plant products, i.e., phytoestrogens (PE), interfere with or alter the development or function of the endocrine system. Although PEs have been studied intensively with regard to the effects on the reproductive organs, such as the uterus or mammary gland, surprisingly little data are available about the effects of PEs on the heart. Here, we conducted a long-term study with ovariectomized mice to examine putative estrogenic effects of the PEs genistein (GEN), resveratrol (RES), and equol (EQ), using estradiol (E2) as a reference compound on heart size, morphology, and cardiac gene expression. We report for the first time significant changes in these parameters by GEN and E2. Changes in the size of cardiomyocytes were observed by GEN and E2. In line with these observations, cardiac expression of insulin-like growth factor 1 (Igf1) was significantly induced by both GEN and E2. Thus, we speculate that endocrine active compounds, like the isoflavone GEN, which is used as a food additive or as a drug for the treatment of menopausal symptoms, may directly affect heart function.

Key words

cardiac gene expression - equol - estradiol - genistein - long-term treatment - phytoestrogens - resveratrol

References

• 1 Isles C G, Hole D J, Hawthorne V M, Lever A F. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men.  Lancet. 1992;  339 702-706
• 2 Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.  Prog Cardiovasc Dis. 1995;  38 199-210
• 3 Rees M, Stevenson J. Primary prevention of coronary heart disease in women.  Menopause Int. 2008;  14 40-45
• 4 Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, Kotchen J M, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
• 5 Arias-Loza P A, Jazbutyte V, Pelzer T. Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system.  Gend Med. 2008;  5 (Suppl. A) S34-S45
• 6 Kararigas G, Becher E, Mahmoodzadeh S, Knosalla C, Hetzer R, Regitz-Zagrosek V. Sex-specific modification of progesterone receptor expression by 17beta-oestradiol in human cardiac tissues.  Biol Sex Differ. 2010;  1 2
• 7 Ling S, Komesaroff P, Sudhir K. Cellular mechanisms underlying the cardiovascular actions of oestrogens.  Clin Sci (Lond). 2006;  111 107-118
• 8 Grohe C, Kahlert S, Lobbert K, Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis.  J Endocrinol. 1998;  156 R1-R7
• 9 Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, Bass J, Bethke N, Zurbrugg H R, Pregla R, Hetzer R, Regitz-Zagrosek V. Upregulation of myocardial estrogen receptors in human aortic stenosis.  Circulation. 2004;  110 3270-3275
• 10 Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz Noppinger P, Kintscher U, Gustafsson J A, Regitz-Zagrosek V. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload.  Am J Physiol Regul Integr Comp Physiol. 2010;  298 R1597-R1606
• 11 Kararigas G, Fliegner D, Gustafsson J A, Regitz-Zagrosek V. Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy.  Physiol Genomics. 2011;  43 438-446
• 12 Regitz-Zagrosek V, Wintermantel T M, Schubert C. Estrogens and SERMs in coronary heart disease.  Curr Opin Pharmacol. 2007;  7 130-139
• 13 Saltiki K, Alevizaki M. Coronary heart disease in postmenopausal women; the role of endogenous estrogens and their receptors.  Hormones (Athens). 2007;  6 9-24
• 14 Carlson S, Peng N, Prasain J K, Wyss J M. Effects of botanical dietary supplements on cardiovascular, cognitive, and metabolic function in males and females.  Gend Med. 2008;  5 (Suppl. A) S76-S90
• 15 Messina M J, Wood C E. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary.  Nutr J. 2008;  7 17
• 16 Wuttke W, Jarry H, Seidlova-Wuttke D. Isoflavones–safe food additives or dangerous drugs?.  Ageing Res Rev. 2007;  6 150-188
• 17 Mazur W, Adlercreutz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health.  Nutrition. 2000;  16 654-658
• 18 Munro I C, Harwood M, Hlywka J J, Stephen A M, Doull J, Flamm W G, Adlercreutz H. Soy isoflavones: a safety review.  Nutr Rev. 2003;  61 1-33
• 19 Luczak E D, Leinwand L A. Sex-based cardiac physiology.  Annu Rev Physiol. 2009;  71 1-18
• 20 Owens J W, Ashby J. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: in support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Organisation for Economic Co-operation and Development.  Crit Rev Toxicol. 2002;  32 445-520
• 21 Kuiper G G, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.  Endocrinology. 1997;  138 863-870
• 22 Bowers J L, Tyulmenkov V V, Jernigan S C, Klinge C M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.  Endocrinology. 2000;  141 3657-3667
• 23 Valenzano D R, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate.  Curr Biol. 2006;  16 296-300
• 24 Mueller S O, Simon S, Chae K, Metzler M, Korach K S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells.  Toxicol Sci. 2004;  80 14-25
• 25 Bottner M, Christoffel J, Jarry H, Wuttke W. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats.  J Endocrinol. 2006;  189 77-88
• 26 Rachon D, Seidlova-Wuttke D, Vortherms T, Wuttke W. Effects of dietary equol administration on ovariectomy induced bone loss in Sprague-Dawley rats.  Maturitas. 2007;  58 308-315
• 27 Sehmisch S, Hammer F, Christoffel J, Seidlova-Wuttke D, Tezval M, Wuttke W, Stuermer K M, Stuermer E K. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis.  Planta Med. 2008;  74 794-801
• 28 Seidlova-Wuttke D, Jarry H, Wuttke W. Effects of estradiol benzoate, raloxifen and an ethanolic extract of Cimicifuga racemosa in nonclassical estrogen regulated organs of ovariectomized rats.  Planta Med. 2009;  75 1279-1285
• 29 Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert R H, Thelen P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.  Mol Cancer Ther. 2007;  6 2626-2633
• 30 Roth C, Schricker M, Lakomek M, Strege A, Heiden I, Luft H, Munzel U, Wuttke W, Jarry H. Autoregulation of the gonadotropin-releasing hormone (GnRH) system during puberty: effects of antagonistic versus agonistic GnRH analogs in a female rat model.  J Endocrinol. 2001;  169 361-371
• 31 Babiker F A, Lips D J, Delvaux E, Zandberg P, Janssen B J, Prinzen F, van Eys G, Grohe C, Doevendans P A. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms.  Acta Physiol (Oxf). 2007;  189 23-31
• 32 Arias-Loza P A, Hu K, Dienesch C, Mehlich A M, Konig S, Jazbutyte V, Neyses L, Hegele-Hartung C, Heinrich Fritzemeier K, Pelzer T. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats.  Hypertension. 2007;  50 432-438
• 33 Patten R D, Pourati I, Aronovitz M J, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn M E, Karas R H. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling.  Circ Res. 2004;  95 692-699
• 34 Vandenbroucke J P. The HRT controversy: observational studies and RCTs fall in line.  Lancet. 2009;  373 1233-1235
• 35 Rachon D, Vortherms T, Seidlova-Wuttke D, Wuttke W. Effects of dietary equol on the pituitary of the ovariectomized rats.  Horm Metab Res. 2007;  39 256-261
• 36 Prentice R L, Langer R D, Stefanick M L, Howard B V, Pettinger M, Anderson G L, Barad D, Curb J D, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.  Am J Epidemiol. 2006;  163 589-599
• 37 van Eickels M, Grohe C, Cleutjens J P, Janssen B J, Wellens H J, Doevendans P A. 17beta-estradiol attenuates the development of pressure-overload hypertrophy.  Circulation. 2001;  104 1419-1423
• 38 Persky A M, Green P S, Stubley L, Howell C O, Zaulyanov L, Brazeau G A, Simpkins J W. Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro.  Proc Soc Exp Biol Med. 2000;  223 59-66
• 39 Munoz-Castaneda J R, Montilla P, Munoz M C, Bujalance I, Muntane J, Tunez I. Effect of 17-beta-estradiol administration during adriamycin-induced cardiomyopathy in ovariectomized rat.  Eur J Pharmacol. 2005;  523 86-92
• 40 Pedram A, Razandi M, Aitkenhead M, Levin E R. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1.  J Biol Chem. 2005;  280 26339-26348
• 41 Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D. Postmenopausal hormone replacement therapy: scientific review.  JAMA. 2002;  288 872-881
• 42 Chao W, Matsui T, Novikov M S, Tao J, Li L, Liu H, Ahn Y, Rosenzweig A. Strategic advantages of insulin-like growth factor-I expression for cardioprotection.  J Gene Med. 2003;  5 277-286
• 43 Geraldes P, Sirois M G, Tanguay J F. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation.  Circ Res. 2003;  93 399-405
• 44 Rachon D, Vortherms T, Seidlova-Wuttke D, Wuttke W. Effects of dietary equol on body weight gain, intra-abdominal fat accumulation, plasma lipids, and glucose tolerance in ovariectomized Sprague-Dawley rats.  Menopause. 2007;  14 925-932
• 45 Miao C Y, Li Z Y. The role of perivascular adipose tissue in vascular smooth muscle cell growth.  Br J Pharmacol. advance online publication 2011;  DOI: 10.1111/j.1476-5381.2011.01404.x